Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving sunitinib malate together with capecitabine works
in treating patients with unresectable or metastatic liver cancer. Sunitinib malate may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor. Drugs used in chemotherapy, such as capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving sunitinib malate together with capecitabine may kill more tumor
cells